<DOC>
	<DOCNO>NCT00004829</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety efficacy tobramycin patient cystic fibrosis chronically colonize Pseudomonas aeruginosa . II . Determine whether treatment produce tobramycin-resistant bacteria frequency different placebo group whether emergence resistance associate lack clinical response .</brief_summary>
	<brief_title>Phase III Randomized Study Inhalation Tobramycin Patients With Cystic Fibrosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients receive tobramycin placebo inhalation twice daily 28 day follow 28 day rest . This treatment repeat twice , total 3 course therapy . Patients follow every 2 week first 8 week , every 4 week , 4 week last treatment .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Documented cystic fibrosis Pseudomonas aeruginosa present sputum throat culture within 6 month prior screen Sweat chloride least 60 mEq/L Prior/Concurrent Therapy At least 14 day since prior intravenous aerosolize tobramycin antipseudomonal antibiotic At least 4 week since prior administration investigational drug No concurrent antibiotic aerosol Patient Characteristics Renal : Creatinine le 2 mg/dL BUN le 40 mg/dL No proteinuria 2+ great Pulmonary : FEV1 least 75 % least 25 % predict Room air oximetry least 88 % saturation Able perform pulmonary function test No hemoptysis 60 mL great within 30 day prior study No abnormal chest Xray Other : Not pregnant Fertile female must use effective contraception No history positive culture Burkholderia cepacia No history glucose6phosphate dehydrogenase deficiency No known local systemic hypersensitivity aminoglycosides , albuterol , beta2 agonist</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1998</verification_date>
	<keyword>bacterial infection</keyword>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>